Home Featured Page 152

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

1...151152153...303 Page 152 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Interview | Josh Ismin, Psylo

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY